The above results revealed that TFAP2A targets ESR2 and activates the MAPK signalling pathway, suggesting that inhibiting ESR2 may sensitise NSCLC cells to targeted therapy. The gene discussed is ESR2; the disease is non-small cell lung carcinoma.